摘要
Stage IV pancreatic ductal adenocarcinoma(PDAC)is considered unresectable by the European Society for Medical Oncology(ESMO)-European Society of Digestive Oncology(ESDO)Clinical Practice Guidelines,and treatment for these patients,remains mostly palliative(1).In non-metastatic PDAC,and whenever feasible,surgery remains a crucial component,playing a key role in improving survival rates.While the general trend has been to prepare as many patients as possible for surgical intervention,the necessity for proper patient selection has become increasingly evident(2).
基金
funded by Bengt Ihre fellowship research grant(to R.V.),Cancerforkningsfonden i Norrland/Lions,Cancerforskningsfond(Nos.AMP 21-1058 and LP 24-2376,to R.V.)
Centrala(No.ALF RV-980274,to R.V.).
